Search

Your search keyword '"Yamaguchi, Kensei"' showing total 1,263 results
Start Over Author "Yamaguchi, Kensei"
1,263 results on '"Yamaguchi, Kensei"'

2. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial

Author

Boku, Narikazu, Omori, Takeshi, Shitara, Kohei, Sakuramoto, Shinichi, Yamaguchi, Kensei, Kato, Ken, Kadowaki, Shigenori, Tsuji, Kunihiro, Ryu, Min-Hee, Oh, Do-Youn, Oh, Sang Cheul, Rha, Sun Young, Lee, Keun-Wook, Chung, Ik-Joo, Sym, Sun Jin, Chen, Li-Tzong, Chen, Jen-Shi, Bai, Li-Yuan, Nakada, Takashi, Hagihara, Shunsuke, Makino, Reina, Nishiyama, Eiji, and Kang, Yoon-Koo

Published
2024
Full Text
View/download PDF

5. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.

Author

Wainberg, Zev, Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang, Li, Jin, Turk, Haci, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian, Cardellino, Giovanni, Sanchez, Raquel, Zahlten-Kümeli, Anita, Taylor, Kate, and Enzinger, Peter

Subjects
Bemarituzumab, FGFR2b, Gastric cancer, Targeted therapy, mFOLFOX6, Humans, Stomach Neoplasms, Fluorouracil, Receptor, Fibroblast Growth Factor, Type 2, Adenocarcinoma, Esophagogastric Junction, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Antibodies, Monoclonal, Humanized
Abstract

BACKGROUND: We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 + /3 + membranous staining by immunohistochemistry), HER-2-negative gastric or gastroesophageal junction cancer (GC). METHODS: Patients received bemarituzumab (15 mg/kg) or placebo once every 2 weeks with an additional bemarituzumab (7.5 mg/kg) or placebo dose on cycle 1 day 8. All patients received mFOLFOX6. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, and safety. Efficacy was evaluated after a minimum follow-up of 24 months. RESULTS: In the bemarituzumab-mFOLFOX6 (N = 77) and placebo-mFOLFOX6 (N = 78) arms, respectively, 59.7% and 66.7% of patients were FGFR2b-positive in ≥ 10% of tumor cells. The median PFS (95% confidence interval [CI]) was 9.5 months (7.3-13.7) with bemarituzumab-mFOLFOX6 and 7.4 months (5.7-8.4) with placebo-mFOLFOX6 (hazard ratio [HR], 0.72; 95% CI 0.49-1.08); median OS (95% CI) was 19.2 (13.6-24.2) and 13.5 (9.3-15.9) months, respectively (HR 0.77; 95% CI 0.52-1.14). Observed efficacy in FGFR2b-positive GC in ≥ 10% of tumor cells was: PFS: HR 0.43 (95% CI 0.26-0.73); OS: HR 0.52 (95% CI 0.31-0.85). No new safety findings were reported. CONCLUSIONS: In FGFR2b-positive advanced GC, the combination of bemarituzumab-mFOLFOX6 led to numerically longer median PFS and OS compared with mFOLFOX6 alone. Efficacy was more pronounced with FGFR2b overexpression in ≥ 10% of tumor cells. Confirmatory phase 3 trials are ongoing (NCT05052801, NCT05111626). CLINICAL TRIAL REGISTRATION: NCT03694522.

Published
2024

9. Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy

Author

Osumi, Hiroki, Shinozaki, Eiji, Nakamura, Yoshiaki, Esaki, Taito, Yasui, Hisateru, Taniguchi, Hiroya, Satake, Hironaga, Sunakawa, Yu, Komatsu, Yoshito, Kagawa, Yoshinori, Denda, Tadamichi, Shiozawa, Manabu, Satoh, Taroh, Nishina, Tomohiro, Goto, Masahiro, Takahashi, Naoki, Kato, Takeshi, Bando, Hideaki, Yamaguchi, Kensei, and Yoshino, Takayuki

Published
2024
Full Text
View/download PDF

10. Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study

Author

Fukuda, Koshiro, Osumi, Hiroki, Yoshinami, Yuri, Ooki, Akira, Takashima, Atsuo, Wakatsuki, Takeru, Hirano, Hidekazu, Nakayama, Izuma, Ouchi, Kota, Sawada, Ryoichi, Fukuoka, Shota, Ogura, Mariko, Takahari, Daisuke, Chin, Keisho, Shoji, Hirokazu, Okita, Natsuko, Kato, Ken, Ishizuka, Naoki, Boku, Narikazu, Yamaguchi, Kensei, and Shinozaki, Eiji

Published
2024
Full Text
View/download PDF

11. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.

Author

Yoshino, Takayuki, Di Bartolomeo, Maria, Raghav, Kanwal, Masuishi, Toshiki, Loupakis, Fotios, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Wainberg, Zev, Elez, Elena, Rodriguez, Javier, Fakih, Marwan, Ciardiello, Fortunato, Saxena, Kapil, Kobayashi, Kojiro, Bako, Emarjola, Okuda, Yasuyuki, Meinhardt, Gerold, Grothey, Axel, Siena, Salvatore, and DESTINY-CRC01 investigators

Subjects
DESTINY-CRC01 investigators, Humans, Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Camptothecin, Receptor, erbB-2, Immunoconjugates, Female, Antibodies, Monoclonal, Humanized, Trastuzumab, Receptor, ErbB-2, Clinical Research, Clinical Trials and Supportive Activities, Colo-Rectal Cancer, Cancer, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals
Abstract

DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are published. Patients received T-DXd 6.4 mg/kg every 3 weeks and were assigned to either: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+), cohort B (IHC 2+/ISH-), or cohort C (IHC 1+). Primary endpoint was objective response rate (ORR) by independent central review in cohort A. Secondary endpoints included ORR (cohorts B and C), duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and safety of T-DXd. 86 patients were enrolled (53 in cohort A, 15 in cohort B, and 18 in cohort C). Results of the primary analysis are published, reporting an ORR of 45.3% in cohort A. Here, we report the final results. No responses occurred in cohorts B or C. Median progression-free survival, overall survival, and duration of response were 6.9, 15.5, and 7.0 months, respectively. Overall serum exposure (cycle 1) of T-DXd, total anti-HER2 antibody, and DXd were similar regardless of HER2 status. Most common grade ≥3 treatment-emergent adverse events were decreased neutrophil count and anemia. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8 patients (9.3%). These findings support the continued exploration of T-DXd in HER2-positive mCRC.

Published
2023

12. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells

Author

Chen, Mingjue, Mashima, Tetsuo, Oishi, Taichi, Muramatsu, Yukiko, Seto, Yosuke, Takamatsu, Manabu, Kawata, Naomi, Morino, Shun, Nakamura, Ayane, Inaba, Saori, Yuan, Xunmei, Maruyama, Kohei, Suzuki, Mai, Sato, Ayana, Yoshida, Haruka, Jang, Myung-Kyu, Mizutani, Anna, Takeuchi, Kengo, Yamaguchi, Kensei, Shirai, Fumiyuki, Nagayama, Satoshi, Katayama, Ryohei, and Seimiya, Hiroyuki

Published
2024
Full Text
View/download PDF

14. Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study

Author

Ogata, Takatsugu, Narita, Yukiya, Wainberg, Zev A, Van Cutsem, Eric, Yamaguchi, Kensei, Piao, Yongzhe, Zhao, Yumin, Peterson, Patrick M, Wijayawardana, Sameera R, Abada, Paolo, Chatterjee, Anindya, and Muro, Kei

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Cancer, Rare Diseases, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Ramucirumab, Stomach neoplasms, Vascular endothelial growth factors
Abstract

PurposeLiver metastasis (LM) is reported in approximately 40% of patients with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma (metastatic esophagogastric adenocarcinoma; mGEA) and is associated with a worse prognosis. This post-hoc analysis from the RAINBOW trial reported the efficacy, safety, and biomarker outcomes of ramucirumab and paclitaxel combination treatment (RAM+PAC) in patients with (LM+) and without (LM-) LM at baseline.Materials and methodsPatients (n=665) were randomly assigned on a 1:1 basis to receive either RAM+PAC (LM+: 150, LM-: 180) or placebo and paclitaxel (PL+PAC) (LM+: 138, LM-: 197). The overall survival (OS) and progression-free survival (PFS) were evaluated using stratified Kaplan-Meier and Cox regression models. The correlation of dichotomized biomarkers (VEGF-C, D; VEGFR-1,2) with efficacy in the LM+ versus LM- subgroups was analyzed using the Cox regression model with reported interaction P-values.ResultsThe presence of LM was associated with earlier progression than those without LM, particularly in patients receiving PL+PAC (hazard ratio [HR], 1.68). RAM+PAC treatment improved OS and PFS irrespective of LM status but showed greater improvement in LM+ than that in LM- (OS HR, 0.71 [LM+] vs. 0.88 [LM-]; PFS HR, 0.47 [LM+] vs. 0.76 [LM-]). Treatment-emergent adverse events were similar between patients with and without LM. No predictive relationship was observed between biomarker levels (VEGF-C, D; VEGFR-1,2) and efficacy outcome (OS, PFS) (all interaction P-values >0.05).ConclusionsRAM provided a significant benefit, irrespective of LM status; however, its effect was numerically stronger in patients with LM. Therefore, RAM+PAC is a clinically meaningful therapeutic option for patients with mGEA and LM.Trial registrationClinicalTrials.gov Identifier: NCT01170663.

Published
2023

15. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

Author

Raghav, Kanwal, Siena, Salvatore, Takashima, Atsuo, Kato, Takeshi, Van den Eynde, Marc, Pietrantonio, Filippo, Komatsu, Yoshito, Kawakami, Hisato, Peeters, Marc, Andre, Thierry, Lonardi, Sara, Yamaguchi, Kensei, Tie, Jeanne, Castro, Cristina Gravalos, Hsu, Hung-Chih, Strickler, John H, Kim, Tae-You, Cha, Yongjun, Barrios, Daniel, Yan, Qi, Kamio, Takahiro, Kobayashi, Kojiro, Boran, Aislyn, Koga, Makito, Allard, John D, and Yoshino, Takayuki

Published
2024
Full Text
View/download PDF

16. Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study

Author

Kawabata, Ryohei, Chin, Keisho, Takahari, Daisuke, Hosaka, Hisashi, Muto, Osamu, Shindo, Yoshiaki, Nagata, Naoki, Yabusaki, Hiroshi, Imamura, Hiroshi, Endo, Shunji, Kashiwada, Tomomi, Nakamura, Masato, Hihara, Jun, Kobayashi, Michiya, Sagawa, Tamotsu, Saito, Soh, Sato, Atsushi, Yamada, Takeshi, Okano, Naohiro, Shimada, Ken, Matsushima, Masashi, Kataoka, Masato, Matsumoto, Shigemi, Goto, Masahiro, Kotaka, Masahito, Shiraishi, Takeshi, Yamai, Hiromichi, Nagashima, Fumio, Ishizuka, Naoki, and Yamaguchi, Kensei

Published
2023
Full Text
View/download PDF

20. Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Author

Muro, Kei, Shitara, Kohei, Yamaguchi, Kensei, Yoshikawa, Takaki, Satake, Hironaga, Hara, Hiroki, Sugimoto, Naotoshi, Machida, Nozomu, Goto, Masahiro, Kawakami, Hisato, Amagai, Kenji, Omuro, Yasushi, Esaki, Taito, Hironaka, Shuichi, Nishina, Tomohiro, Komatsu, Yoshito, Matsubara, Hisahiro, Shiratori, Shinichi, Han, Shirong, Satoh, Taroh, and Ohtsu, Atsushi

Published
2023
Full Text
View/download PDF

24. Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study

Author

Takahari, Daisuke, Katai, Hitoshi, Takashima, Atsuo, Izawa, Naoki, Ishizuka, Naoki, Ohashi, Manabu, Mikami, Shinya, Wakatsuki, Takeru, Nakayama, Izuma, Chin, Keisho, Ida, Satoshi, Kumagai, Koshi, Nunobe, Souya, Iwasa, Satoru, Shoji, Hirokazu, Wada, Takeyuki, Doi, Ayako, Yoshikawa, Takaki, Sano, Takeshi, Boku, Narikazu, and Yamaguchi, Kensei

Published
2023
Full Text
View/download PDF

27. Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant

Author

Nakai, Chikako, Mimaki, Sachiyo, Matsushima, Koutatsu, Shinozaki, Eiji, Yamazaki, Kentaro, Muro, Kei, Yamaguchi, Kensei, Nishina, Tomohiro, Yuki, Satoshi, Shitara, Kohei, Bando, Hideaki, Suzuki, Yutaka, Akagi, Kiwamu, Nomura, Shogo, Fujii, Satoshi, Sugiyama, Masaya, Nishida, Nao, Mizokami, Masashi, Koh, Yasuhiro, Koshizaka, Takuya, Okada, Hideki, Abe, Yukiko, Ohtsu, Atsushi, Yoshino, Takayuki, and Tsuchihara, Katsuya

Published
2023
Full Text
View/download PDF

28. Adding Induction Chemotherapy Before Chemoradiotherapy with Total Mesorectal Excision and Selective Lateral Lymph Node Dissection for Patients with Poor-Risk, Locally Advanced, Mid-to-Low Rectal Cancer May Improve Oncologic Outcomes: A Propensity Score-Matched Analysis

Author

Yamaguchi, Tomohiro, Akiyoshi, Takashi, Fukunaga, Yosuke, Sakamoto, Takashi, Mukai, Toshiki, Hiyoshi, Yukiharu, Nagasaki, Toshiya, Taguchi, Senzo, Chino, Akiko, Shinozaki, Eiji, Yamaguchi, Kensei, and Konishi, Tsuyoshi

Published
2023
Full Text
View/download PDF

30. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Author

Mendez, Guillermo, O'Connor, Juan Manuel, Yanzi Castilla, Alvaro, Cundom, Juan, Kaen, Diego, Wong, Rachel, Ng, Weng, Aghmesheh, Morteza, Peressoni, Mauricio, Andrade, Carlos, Franke, Fabio, Alves, Gustavo, Cruz, Felipe Jose, Vianna, Karina, Monteiro, Maria Marcela, Raphael, Michael, Berry, Scott, Jang, Raymond, Tan, Ann, Asselah, Jamil, Yanez Weber, Patricio, Mahave, Mauricio, Sanchez, Cesar, Salman, Pamela, Bai, Yuxian, Li, Jin, Zhang, Xiaochun, Liu, Tianshu, Lin, Xiaoyan, Qin, Shukui, Yang, Jianwei, Luo, Suxia, Li, Wei, Ying, Jieer, Chen, Xi, Zeng, Shan, Qu, Yanli, Yang, Lin, Zhao, Lin, Chen, Ping, Pan, Hongming, Li, Enxiao, Ye, Feng, Lu, Jianwei, Liang, Xinjun, Zhao, Qun, Yin, Xianli, Li, Junhe, Ling, Yang, Lv, Guoqing, Li, Shouguo, Guerrero, Alvaro, Rubiano, Juan, Gonzalez Fernandez, Manuel, Manneh Kopp, Ray, Guzman Ramirez, Adrian, Corrales, Luis, Gonzalez Herrera, Ileana, Melichar, Bohuslav, Buchler, Tomas, Svoboda, Tomas, Obermannova, Radka, Vrana, David, Cvek, Jakub, Pfeiffer, Per, Baeksgaard, Lene, Yilmaz, Mette, Boige, Valerie, Lopez-Trabada, Daniel, Borg, Christophe, Pannier, Diane, Hiret, Sandrine, Di Fiore, Frederic, Metges, Jean-Philippe, Arnold, Dirk, Martens, Uwe, Lordick, Florian, Stein, Alexander, Castro, Hugo, Lopez, Karla, Ramirez, Julio, Aguilar, Mynor, Chivalan, Marco, Chan, Wendy, Cheng, Ashley, Yeo, Winnie, Arkosy, Peter, Csoszi, Tibor, Hitre, Erika, Horvath, Zsolt, Lowery, Maeve, McDermott, Ray, Morris, Patrick, Hubert, Ayala, Brenner, Baruch, Ben-Aharon, Irit, Shacham-Shmueli, Einat, Man, Sofia, Pelles Avraham, Sharon, Brenner, Ronen, Mishaeli, Moshe, Di Bartolomeo, Maria, Fazio, Nicola, Lonardi, Sara, Garufi, Carlo, Satoh, Taroh, Hara, Hiroki, Iwagami, Shiro, Yasui, Hisateru, Tsuda, Masahiro, Shimoyama, Tatsu, Shoji, Hirokazu, Sugimoto, Naotoshi, Shibata, Nobuhiro, Yamaguchi, Kensei, Amagai, Kenji, Choda, Yasuhiro, Esaki, Taito, Yabusaki, Hiroshi, Oshima, Takashi, Tsuji, Akihito, Kawakami, Hisato, Kawazoe, Akihito, Ishido, Kenji, Kadowaki, Shigenori, Martinez Rodriguez, Jorge, Herrera Martinez, Marytere, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Balancan, Paola, Damianovich, Dragan, Castro Oliden, Victor, Grados, Julio, Torres, Cesar, Wyrwicz, Lucjan, Wysocki, Piotr, Hajac, Lukasz, Zolnierek, Jakub, Karaszewska, Boguslawa, Rha, Sun Young, Lee, Jeeyun, Ryu, Min-Hee, Oh, Do-Youn, Orlova, Rashida, Tjulandin, Sergey, Fadeeva, Natalia, Makarycheva, Yulia, Nosov, Dmitry, Smagina, Maria, Chan, Sze, Jacobs, Conrad, Kraus, Peter, Landers, Gregory, Robertson, Barbara, Ruff, Paul, Schoeman, Elizabeth, Maurel, Jean-Marc, Diez Garcia, Marc, Jimenez Fonseca, Paula, Gallego Plazas, Javier, Rivera Herrero, Fernando, Miranda Poma, Jesus, Layos Romero, Laura, Fritsch, Ralph, Bastian, Sara, Winterhalder, Ralph, Dosso, Sara De, Kossler, Thibaud, Yeh, Kun-Huei, Yen, Chia-Jui, Chen, Yen-Yang, Lin, Johnson, Bilici, Mehmet, Ozguroglu, Mustafa, Cil, Timucin, Oksuzoglu, Berna, Harputluoglu, Hakan, Karaoglu, Aziz, Hacibekiroglu, Ilhan, Erdogan, Bulent, Yalcin, Suayib, Adamchuk, Hryhoriy, Bondarenko, Igor, Kolesnik, Oleksii, Ostapenko, Yuriy, Kryzhanivska, Anna, Leshchenko, Lurii, Ilin, Ievgen, Shparyk, Yaroslav, Trukhin, Dmytro, Voitko, Nataliia, Roy, Rajarshi, Young, Anna-Mary, Medley, Louise, Shiu, Kai-Keen, Celano, Paul, Overton, Lindsay, Raj, Moses, Dunne, Richard, Wainberg, Zev, Dayyani, Farshid, Larson, Timothy, Kochenderfer, Mark, Yañez, Patricio, Rivera, Fernando, Alves, Gustavo Vasconcelos, Garrido, Marcelo, Fernández, Manuel González, Lowery, Maeve A, Çil, Timuçin, Cruz, Felipe Melo, Wainberg, Zev A, Yin, Lina, Bordia, Sonal, Bhagia, Pooja, and Wyrwicz, Lucjan S

Published
2023
Full Text
View/download PDF

35. Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study

Author

Shah, Manish A., Yoshino, Takayuki, Tebbutt, Niall C., Grothey, Axel, Tabernero, Josep, Xu, Rui-Hua, Cervantes, Andres, Oh, Sang Cheul, Yamaguchi, Kensei, Fakih, Marwan, Falcone, Alfredo, Wu, Christina, Chiu, Vi K., Tomasek, Jiri, Bendell, Johanna, Fontaine, Marilyn, Hitron, Matthew, Xu, Bo, Taieb, Julien, and Van Cutsem, Eric

Published
2023
Full Text
View/download PDF

37. A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study

Author

Matsumura, Masaru, Hasegawa, Kiyoshi, Oba, Masaru, Yamaguchi, Kensei, Uetake, Hiroyuki, Yoshino, Takayuki, Morita, Satoshi, Takahashi, Keiichi, Unno, Michiaki, Shimada, Yasuhiro, Muro, Kei, Matsuhashi, Nobuhisa, Mori, Masaki, Baba, Hideo, Shimada, Mitsuo, Mise, Yoshihiro, Kawaguchi, Yoshikuni, Kagimura, Tatsuo, Ishigure, Kiyoshi, Saiura, Akio, Sugihara, Kenichi, and Kokudo, Norihiro

Published
2022
Full Text
View/download PDF

38. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Author

Wainberg, Zev A, Enzinger, Peter C, Kang, Yoon-Koo, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, Haci Mehmet, Teixeira, Alexandra, Borg, Christophe, Hitre, Erika, Udrea, Adrian A, Cardellino, Giovanni Gerardo, Sanchez, Raquel Guardeño, Collins, Helen, Mitra, Siddhartha, Yang, Yingsi, Catenacci, Daniel V T, and Lee, Keun-Wook

Published
2022
Full Text
View/download PDF

39. Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy

Author

Aoki, Yu, Nakamura, Yoshiaki, Denda, Tadamichi, Ohta, Takashi, Esaki, Taito, Shiozawa, Manabu, Yamaguchi, Kensei, Yamazaki, Kentaro, Sunakawa, Yu, Kato, Takeshi, Okano, Naohiro, Taniguchi, Hiroya, Sato, Taro, Oki, Eiji, Nishina, Tomohiro, Komatsu, Yoshito, Matsuhashi, Nobuhisa, Goto, Masahiro, Yasui, Hisateru, Ohtsubo, Koushiro, Moriwaki, Toshikazu, Takahashi, Naoki, Horita, Yosuke, Boku, Shogen, Wakabayashi, Masashi, Ikeno, Takashi, Mitani, Ryuta, Yuasa, Mihoko, and Yoshino, Takayuki

Published
2023
Full Text
View/download PDF

41. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Author

Shitara, Kohei, Ajani, Jaffer A., Moehler, Markus, Garrido, Marcelo, Gallardo, Carlos, Shen, Lin, Yamaguchi, Kensei, Wyrwicz, Lucjan, Skoczylas, Tomasz, Bragagnoli, Arinilda Campos, Liu, Tianshu, Tehfe, Mustapha, Elimova, Elena, Bruges, Ricardo, Zander, Thomas, de Azevedo, Sergio, Kowalyszyn, Ruben, Pazo-Cid, Roberto, Schenker, Michael, Cleary, James M., Yanez, Patricio, Feeney, Kynan, Karamouzis, Michalis V., Poulart, Valerie, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun, and Janjigian, Yelena Y.

Published
2022
Full Text
View/download PDF

43. Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial

Author

Ooki, Akira, Morita, Satoshi, Tsuji, Akihito, Iwamoto, Shigeyoshi, Hara, Hiroki, Tanioka, Hiroaki, Satake, Hironaga, Kataoka, Masato, Kotaka, Masahito, Kagawa, Yoshinori, Nakamura, Masato, Shingai, Tatsushi, Ishikawa, Masashi, Miyake, Yasuhiro, Suto, Takeshi, Hashiguchi, Yojiro, Yabuno, Taichi, Ando, Masahiko, Sakamoto, Junichi, and Yamaguchi, Kensei

Published
2022
Full Text
View/download PDF

44. ASO Visual Abstract: Adding Induction Chemotherapy Before Chemoradiotherapy with Total Mesorectal Excision and Selective Lateral Lymph Node Dissection in Patients with Poor-Risk, Locally Advanced, Mid-to-Low Rectal Cancer May Improve Oncological Outcomes—A Propensity Score-Matched Analysis

Author

Yamaguchi, Tomohiro, Akiyoshi, Takashi, Fukunaga, Yosuke, Sakamoto, Takashi, Mukai, Toshiki, Hiyoshi, Yukiharu, Nagasaki, Toshiya, Taguchi, Senzo, Chino, Akiko, Shinozaki, Eiji, Yamaguchi, Kensei, and Konishi, Tsuyoshi

Published
2023
Full Text
View/download PDF

45. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Author

Kang, Yoon-Koo, Chen, Li-Tzong, Ryu, Min-Hee, Oh, Do-Youn, Oh, Sang Cheul, Chung, Hyun Cheol, Lee, Keun-Wook, Omori, Takeshi, Shitara, Kohei, Sakuramoto, Shinichi, Chung, Ik-Joo, Yamaguchi, Kensei, Kato, Ken, Sym, Sun Jin, Kadowaki, Shigenori, Tsuji, Kunihiro, Chen, Jen-Shi, Bai, Li-Yuan, Oh, Sung-Yong, Choda, Yasuhiro, Yasui, Hisateru, Takeuchi, Kentaro, Hirashima, Yoshinori, Hagihara, Shunsuke, and Boku, Narikazu

Published
2022
Full Text
View/download PDF

48. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Author

Qiu, Miao-Zhen, primary, Oh, Do-Youn, additional, Kato, Ken, additional, Arkenau, Tobias, additional, Tabernero, Josep, additional, Correa, Marcia Cruz, additional, Zimina, Anastasia V, additional, Bai, Yuxian, additional, Shi, Jianhua, additional, Lee, Keun-Wook, additional, Wang, Jufeng, additional, Poddubskaya, Elena, additional, Pan, Hongming, additional, Rha, Sun Young, additional, Zhang, Ruixing, additional, Hirano, Hidekazu, additional, Spigel, David, additional, Yamaguchi, Kensei, additional, Chao, Yee, additional, Wyrwicz, Lucjan, additional, Disel, Umut, additional, Cid, Roberto Pazo, additional, Fornaro, Lorenzo, additional, Evesque, Ludovic, additional, Wang, Hongwei, additional, Xu, Yaling, additional, Li, Jiang, additional, Sheng, Tao, additional, Yang, Silu, additional, Li, Liyun, additional, Moehler, Markus, additional, and Xu, Rui-Hua, additional

Published
2024
Full Text
View/download PDF

49. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Author

Shitara, Kohei, primary, Bang, Yung-Jue, additional, Iwasa, Satoru, additional, Sugimoto, Naotoshi, additional, Ryu, Min-Hee, additional, Sakai, Daisuke, additional, Chung, Hyun Cheol, additional, Kawakami, Hisato, additional, Yabusaki, Hiroshi, additional, Sakamoto, Yasuhiro, additional, Nishina, Tomohiro, additional, Inaki, Koichiro, additional, Kuwahara, Yusuke, additional, Wada, Naoya, additional, Suto, Fumitaka, additional, Arita, Takeo, additional, Sugihara, Masahiro, additional, Tsuchihashi, Zenta, additional, Saito, Kaku, additional, Kojima, Akihito, additional, and Yamaguchi, Kensei, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results